Literature DB >> 1396928

May-Hegglin anomaly: a rare cause of thrombocytopenia.

A Greinacher1, J Bux, V Kiefel, J G White, C Mueller-Eckhardt.   

Abstract

A family with four and an unrelated family with three individuals affected by the May-Hegglin anomaly are described. Platelet counts were markedly reduced and were correctly determined only in the counting chamber. Bleeding time and platelet aggregation were always normal, but platelet nucleotide concentrations (ATP and ADP) were elevated. The platelet glycoprotein complexes Ib/IX, IIb/IIIa and Ia/IIa were quantitatively normal. Platelet-associated IgG was slightly elevated, although thrombocytopenia was presumably not caused by an immunological mechanism. Morphological investigations showed giant platelets and spindle-shaped inclusion bodies in the granulocytes, while their function (phagocytic capacity, radical production) was normal. To exclude hereditary types of thrombocytopenia, morphological and family investigations are required to avoid misdiagnosis with far-reaching diagnostic and therapeutic consequences.

Entities:  

Mesh:

Year:  1992        PMID: 1396928     DOI: 10.1007/bf01957570

Source DB:  PubMed          Journal:  Eur J Pediatr        ISSN: 0340-6199            Impact factor:   3.183


  23 in total

1.  Isolation of mononuclear cells and granulocytes from human blood. Isolation of monuclear cells by one centrifugation, and of granulocytes by combining centrifugation and sedimentation at 1 g.

Authors:  A Böyum
Journal:  Scand J Clin Lab Invest Suppl       Date:  1968

2.  May-Hegglin anomaly: a defect in megakaryocyte fragmentation?

Authors:  H A Godwin; A D Ginsburg
Journal:  Br J Haematol       Date:  1974-01       Impact factor: 6.998

3.  Plasma and platelet beta-thromboglobulin levels in patients with May-Hegglin anomaly.

Authors:  F Fabris; A Casonato; M L Randi; A Girolami
Journal:  Haemostasis       Date:  1980

4.  Development of two distinct membrane systems associated in giant complexes in pathological megakaryocytes.

Authors:  J Breton-Gorius
Journal:  Ser Haematol       Date:  1975

5.  Platelet function, ultrastructure, and survival in the May-Hegglin anomaly.

Authors:  R W Hamilton; B S Shaikh; J N Ottie; A E Storch; A Saleem; J G White
Journal:  Am J Clin Pathol       Date:  1980-11       Impact factor: 2.493

6.  Defective neutrophil mobility in the May-Hegglin anomaly.

Authors:  J R Cabrera; G Fontán; F Lorente; C Regidor; M N Fernández
Journal:  Br J Haematol       Date:  1981-03       Impact factor: 6.998

7.  Platelet membrane studies in the May-Hegglin anomaly.

Authors:  B S Coller; M H Zarrabi
Journal:  Blood       Date:  1981-08       Impact factor: 22.113

Review 8.  Congenital disorders of the function of polymorphonuclear neutrophils.

Authors:  E L Mills; P G Quie
Journal:  Rev Infect Dis       Date:  1980 May-Jun

9.  Characterization of the platelet membrane glycoprotein abnormalities in Bernard-Soulier syndrome and comparison with normal by surface-labeling techniques and high-resolution two-dimensional gel electrophoresis.

Authors:  K J Clemetson; J L McGregor; E James; M Dechavanne; E F Lüscher
Journal:  J Clin Invest       Date:  1982-08       Impact factor: 14.808

10.  Congenital macrothrombocytopenia, leucocyte inclusions, deafness and proteinuria: functional and electron microscopic observations on platelets and megakaryocytes.

Authors:  M J Heynen; D Blockmans; R L Verwilghen; J Vermylen
Journal:  Br J Haematol       Date:  1988-12       Impact factor: 6.998

View more
  2 in total

1.  Nonmuscle myosin heavy chain IIA mutations define a spectrum of autosomal dominant macrothrombocytopenias: May-Hegglin anomaly and Fechtner, Sebastian, Epstein, and Alport-like syndromes.

Authors:  K E Heath; A Campos-Barros; A Toren; G Rozenfeld-Granot; L E Carlsson; J Savige; J C Denison; M C Gregory; J G White; D F Barker; A Greinacher; C J Epstein; M J Glucksman; J A Martignetti
Journal:  Am J Hum Genet       Date:  2001-10-04       Impact factor: 11.025

2.  Decreased platelet membrane anisotropy in patients with adrenoleukodystrophy treated with erucic acid (22:1)-rich triglycerides.

Authors:  S Stöckler; C Opper; A Greinacher; D H Hunneman; G C Korenke; C J Unkrig; F Hanefeld
Journal:  J Inherit Metab Dis       Date:  1997-03       Impact factor: 4.982

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.